These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22378262)

  • 21. Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy).
    Cho Y; Baranczak A; Helmke S; Teruya S; Horn EM; Maurer MS; Kelly JW
    Amyloid; 2015; 22(3):175-80. PubMed ID: 26193961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
    Salvi F; Volpe R; Pastorelli F; Bianchi A; Vella A; Rapezzi C; Mascalchi M
    J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):e212-e214. PubMed ID: 29779881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amyloid Polyneuropathy and Myocardial Amyloidosis 10 Years after Domino Liver Transplantation from a Patient with a Transthyretin Ser50Arg Mutation.
    Matsushima M; Yabe I; Tsuda M; Sakakibara M; Shimamura T; Sasaki H
    Intern Med; 2017 Dec; 56(23):3231-3235. PubMed ID: 28943540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy.
    Lamb YN
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):113-121. PubMed ID: 33469827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current and future treatment of amyloid neuropathies.
    Adams D; Cauquil C; Theaudin M; Rousseau A; Algalarrondo V; Slama MS
    Expert Rev Neurother; 2014 Dec; 14(12):1437-51. PubMed ID: 25416603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [What gnaws at the heart and gets on the nerves].
    Kristen AV
    Internist (Berl); 2018 Nov; 59(11):1208-1213. PubMed ID: 30039176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of cardiac transthyretin amyloidosis: an update.
    Emdin M; Aimo A; Rapezzi C; Fontana M; Perfetto F; Seferović PM; Barison A; Castiglione V; Vergaro G; Giannoni A; Passino C; Merlini G
    Eur Heart J; 2019 Dec; 40(45):3699-3706. PubMed ID: 31111153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody therapy for transthyretin-related hereditary amyloid polyneuropathy: another therapeutic option.
    Ando Y; Ueda M
    Amyloid; 2017 Mar; 24(sup1):113-114. PubMed ID: 28434350
    [No Abstract]   [Full Text] [Related]  

  • 29. [Newly developed drug therapies for familial amyloid polyneuropathy: diflunisal and tafamidis].
    Sekijima Y
    Brain Nerve; 2014 Jul; 66(7):773-81. PubMed ID: 24998822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy.
    Huber P; Flynn A; Sultan MB; Li H; Rill D; Ebede B; Gundapaneni B; Schwartz JH
    Amyloid; 2019 Dec; 26(4):203-209. PubMed ID: 31353964
    [No Abstract]   [Full Text] [Related]  

  • 31. Transthyretin (ATTR) amyloidosis nephropathy: lessons from a TTR stabilizer molecule.
    Rocha A; Silva A; Cardoso M; Beirão I; Alves C; Teles P; Coelho T; Lobato L
    Amyloid; 2017 Mar; 24(sup1):81-82. PubMed ID: 28434370
    [No Abstract]   [Full Text] [Related]  

  • 32. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Planté-Bordeneuve V; Lin H; Gollob J; Agarwal S; Betts M; Fahrbach K; Chitnis M; Polydefkis M
    Expert Opin Pharmacother; 2019 Mar; 20(4):473-481. PubMed ID: 30489166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent progress in the understanding and treatment of transthyretin amyloidosis.
    Sekijima Y
    J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
    Merkies IS
    Neurology; 2013 Apr; 80(15):1444-5. PubMed ID: 23569001
    [No Abstract]   [Full Text] [Related]  

  • 35. [Experience with tafamidis in a patient with transthyretin amyloidosis].
    Nasonova SN; Zhirov IV; Magomedov MM; Saidova MA; Osmolovskaya YF; Tereschenko SN
    Kardiologiia; 2020 Jan; 60(3):155-160. PubMed ID: 32375630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy.
    Waddington Cruz M; Amass L; Keohane D; Schwartz J; Li H; Gundapaneni B
    Amyloid; 2016 Sep; 23(3):178-183. PubMed ID: 27494299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy.
    Gundapaneni BK; Sultan MB; Keohane DJ; Schwartz JH
    Eur J Neurol; 2018 Mar; 25(3):464-468. PubMed ID: 29115008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study.
    Planté-Bordeneuve V; Gorram F; Salhi H; Nordine T; Ayache SS; Le Corvoisier P; Azoulay D; Feray C; Damy T; Lefaucheur JP
    J Neurol; 2017 Feb; 264(2):268-276. PubMed ID: 27878441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.
    Bulawa CE; Connelly S; Devit M; Wang L; Weigel C; Fleming JA; Packman J; Powers ET; Wiseman RL; Foss TR; Wilson IA; Kelly JW; Labaudinière R
    Proc Natl Acad Sci U S A; 2012 Jun; 109(24):9629-34. PubMed ID: 22645360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
    Maurer MS; Elliott P; Merlini G; Shah SJ; Cruz MW; Flynn A; Gundapaneni B; Hahn C; Riley S; Schwartz J; Sultan MB; Rapezzi C;
    Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.